Post-earnings recap
Reported
Thu, Nov 7, 2019
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
50%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Axovant Gene Therapies reported a loss of $0.56 per share, which did not meet any consensus expectations. The stock reacted negatively, dropping 9.67%, likely due to the lack of revenue information and guidance. Investors may be concerned about the company's ability to navigate current market challenges without clear direction.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.56 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
Management expressed concerns about current market conditions and the impact on future performance. They did not provide any updates on guidance.
Management did not provide specific guidance for future quarters.
The company acknowledged challenges in meeting market expectations.